title: Comment on 'The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer'.
authors.forename: D
authors.initials: D
authors.lastname: Kitchen
authors.forename: M
authors.initials: M
authors.lastname: O'Brien
authors.forename: B
authors.initials: B
authors.lastname: Hughes
authors.forename: I
authors.initials: I
authors.lastname: Gill
authors.forename: S
authors.initials: S
authors.lastname: Rumbles
authors.forename: P
authors.initials: P
authors.lastname: Ellis
authors.forename: J
authors.initials: J
authors.lastname: Stebbing
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D043823:Taxoids / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000097:blood*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D042461:Vascular Endothelial Growth Factor A; D040301:Vascular Endothelial Growth Factor Receptor-2